PRQR Key Statistics, Chart & Performance
The current stock price of PRQR is 1.55 USD. In the past month the price decreased by -22.11%. In the past year, price decreased by -31.11%.
PRQR Technical Analysis
PRQR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRQR. Both the profitability and financial health of PRQR have multiple concerns.
PRQR Financial Highlights
Over the last trailing twelve months PRQR reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS decreased by -42.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.23% | ||
| ROE | -74.59% | ||
| Debt/Equity | 0.18 |
PRQR Forecast & Estimates
15 analysts have analysed PRQR and the average price target is 9.82 USD. This implies a price increase of 533.39% is expected in the next year compared to the current price of 1.55.
For the next year, analysts expect an EPS growth of -39.17% and a revenue growth -24.87% for PRQR
PRQR Ownership
About PRQR
Company Profile
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 166 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Company Info
PROQR THERAPEUTICS NV
Zernikedreef 9
Leiden ZUID-HOLLAND 2333 CK NL
CEO: Daniel de Boer
Employees: 166
Phone: 31881667000
PROQR THERAPEUTICS NV / PRQR FAQ
What does PROQR THERAPEUTICS NV do?
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 166 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Can you provide the latest stock price for PROQR THERAPEUTICS NV?
The current stock price of PRQR is 1.55 USD. The price decreased by -4.32% in the last trading session.
Does PRQR stock pay dividends?
PRQR does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRQR stock?
PRQR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for PRQR stock?
PROQR THERAPEUTICS NV (PRQR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.49).
Can you provide the growth outlook for PROQR THERAPEUTICS NV?
The Revenue of PROQR THERAPEUTICS NV (PRQR) is expected to decline by -24.87% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.